FDA Approves First RNA-Targeted Therapy for HAE

Published on: LinkedIn (Spencer Knight)

The U.S. FDA has approved DAWNZERA (donidalorsen) from Ionis Pharmaceuticals, the first RNA-targeted prophylactic therapy for hereditary angioedema (HAE) in patients 12 years and older. Clinical trials showed up to 90% reduction in moderate-to-severe attacks and long-term durability, offering new hope for the 7,000 people in the U.S. living with this rare, life-threatening condition.

👉 Read the full article: First-in-Class Breakthrough in HAE

Disclaimer:

Images used are for illustrative purposes only and do not depict actual persons, products, or facilities. For full detail, refer to the original article via the provided link.